Amgen, the world's largest biotechnology company, is set to add several anticancer drug treatments to its portfolio after agreeing to pay $10.4 billion to acquire Onyx Pharmaceuticals. Sullivan & Cromwell is advising Amgen, while Onyx has turned to Goodwin Procter.
S&C, Goodwin Lead on $10 Billion Amgen-Onyx Deal
The Am Law Daily
August 26, 2013